{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-008841","form_type":"8-K","ticker":"LFMD","cik":"0000948320","company_name":"LifeMD, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.912506+00:00","generated_at":"2026-05-22T16:00:39.427860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LifeMD Q1 revenue up 49% to $65.7M; first GAAP profit; raises FY 2025 guidance","bullets":["Total revenue $65.7M (+49% YoY); telehealth revenue up 70% to $55.8M.","GAAP net income $0.6M ($0.01 diluted EPS), first-ever positive GAAP EPS.","Adj. EBITDA $8.7M (vs. $0.1M); telehealth adj. EBITDA $5.3M (vs. -$1.3M).","FY 2025 guidance raised: revenue $268-275M, adj. EBITDA $31-33M.","Partnered with LillyDirect/NovoCare for branded GLP-1 access (Zepbound, Wegovy)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-008841","json":"https://secwatch.observer/filing/0001641172-25-008841.json","markdown":"https://secwatch.observer/filing/0001641172-25-008841.md","text":"https://secwatch.observer/filing/0001641172-25-008841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/948320/000164117225008841/0001641172-25-008841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/948320/000164117225008841/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:00:39.427860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}